22.29 -0.94 (-4.02%)
OGXI
Stock Details
Last Trade:22.29 Change:-0.94 (-4.02%) Prev Close:23.23 Open: 23.40 Days Range:21.63 – 23.40 52 Week Range: 2.00 - 27.05 Volume:133290 P/E: N/AEPS:-3.38
View AllRecent Alerts 07/04/09
Recent Alert on 06/26/09 at 4:06pm
OncoGenex Pharmaceuticals (OGXI) Files Shelf Registration Statement
OncoGenex Pharmaceuticals (OGXI) Files Shelf Registration Statement
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) has filed a shelf registration statement on Form S-3 with the US Securities and Exchange Commission and an MJDS prospectus under the multi-jurisdictional disclosure system in the Province of British... Read More
Recent Alert on 06/24/09 at 9:33am
Morning Movers 6/24: TTGT, CUR, CYAN, OCLS, AM Higher; PQ, SVU Lower
Morning Movers 6/24: TTGT, CUR, CYAN, OCLS, AM Higher; PQ, SVU Lower
Recent Alert on 06/24/09 at 8:10am
OncoGenex Pharmaceuticals (OGXI) Completes Amendment to Phase 3 for Confirming Survival Benefit in Patients with First-Line Docetaxel for Metastatic Prostate Cancer
OncoGenex Pharmaceuticals (OGXI) Completes Amendment to Phase 3 for Confirming Survival Benefit in Patients with First-Line Docetaxel for Metastatic Prostate Cancer
Recent Alert on 06/24/09 at 8:10am
OncoGenex Pharmaceuticals (OGXI) Completes Amendment to Phase 3 for Confirming Survival Benefit in Patients with First-Line Docetaxel for Metastatic Prostate Cancer
OncoGenex Pharmaceuticals (OGXI) Completes Amendment to Phase 3 for Confirming Survival Benefit in Patients with First-Line Docetaxel for Metastatic Prostate Cancer
Recent Alert on 06/05/09 at 6:06pm
Top 10 News Items 6/1-6/5: GM IS BANKRUPT; Jobs Report Comes in Much Better-Than-Expected; Equity Offerings Still All The Rage
Top 10 News Items 6/1-6/5: GM IS BANKRUPT; Jobs Report Comes in Much Better-Than-Expected; Equity Offerings Still All The Rage
View AllRecent Press Releases
View AllRecent SEC Filings
No Recent SEC Filings Available
View AllRecent Blog Posts
Blog Posts on 06/19/09 at 8:36am
Molecular Insight Pharmaceuticals: Two Promising Candidates to Battle Prostate Cancer
Molecular Insight Pharmaceuticals: Two Promising Candidates to Battle Prostate Cancer